Home
HelpTEST ID CSP53 TP53 Gene Somatic Mutation Pre-Analysis Cell Sorting, Varies
Reporting Name
TP53 Pre-Analysis Cell Sorting, VSpecimen Type
VariesSpecimen Required
Only orderable as a reflex. For more information see P53CA / Hematologic Neoplasms, TP53 Somatic Mutation, DNA Sequencing Exons 4-9, Varies.
Specimen Type: Whole blood
Container/Tube: Lavender top (EDTA) or yellow top (ACD)
Specimen Volume: 3 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. Do not aliquot.
3. Label specimen as blood.
Specimen Minimum Volume
1 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Varies | Ambient (preferred) | 10 days |
| Refrigerated | 10 days |
Method Name
Only orderable as a reflex. For more information see P53CA / Hematologic Neoplasms, TP53 Somatic Mutation, DNA Sequencing Exons 4-9, Varies.
Flow Cytometric Cell Selection
Reject Due To
| Gross hemolysis | Reject |
| Fully clotted | Reject |
Reference Values
Only orderable as a reflex. For more information see P53CA / Hematologic Neoplasms, TP53 Somatic Mutation, DNA Sequencing Exons 4-9, Varies.
Not applicable
Day(s) Performed
Specimens processed: Monday through Sunday
Results reported: Monday through Saturday
Report Available
7 daysSpecimen Retention Time
DNA: 3 monthsPerforming Laboratory
Mayo Clinic Laboratories in Rochester
CPT Code Information
88184-Flow cytometry, first cell surface, cytoplasmic or nuclear marker
88185 x 4-Each additional marker
Useful For
Determination of B-cell content and confirmation the presence of a clonal B-cell population evaluating chronic lymphocytic leukemia patients prior to TP53 variant analysis
Clinical Information
Patients with chronic lymphocytic leukemia (CLL) have variable disease course influenced by a series of tumor biologic factors. The presence of chromosomal 17p- or TP53 gene mutation confers a very poor prognosis to a subset of CLL patients, both at time of initial diagnosis as well as at disease progression, or in the setting of therapeutic resistance. TP53 gene mutation status in CLL has emerged as the single most predictive tumor genetic abnormality associated with adverse outcome and poor response to standard immunochemotherapy; however, patients can be managed with alternative therapeutic options.